Airway Stem Cell Recellularization for Bioartificial Lung Epithelium
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The long wait times and high mortality rates associated with lung transplants for conditions like COPD and cystic fibrosis necessitate the development of techniques to engineer functional lung organs for transplantation, addressing the risk of rejection and the need for efficient cell sources and biomimetic culture conditions.
Innovation Solution
Isolation and expansion of a proliferative basal epithelial stem cell population, utilizing decellularized lung scaffolds with exogenously added tenascin-c and fibrillin-2, and controlling Notch pathways to induce specific epithelial phenotypes, combined with bi-directional ventilation systems for maturation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If lung transplants are used for end-stage organ failure, then patients can receive functional lung tissue, but wait times exceed two years and mortality rate reaches 30%
Solution Approach 1:
The patent applies preliminary action by pre-decellularizing lung scaffolds and preparing them for recellularization before patient need arises. Human basal epithelial stem cells are isolated, expanded, and characterized in advance, then applied to pre-prepared acellular lung matrices, enabling rapid production of bioartificial lungs without waiting for donor organs.
Solution Approach 2:
The patent uses copying by creating acellular lung scaffolds that replicate the native lung extracellular matrix structure. These scaffolds serve as templates that are then repopulated with patient-specific stem cells, producing a copy of functional lung tissue that matches the patient's anatomy without requiring a donor organ.
2Stability of the object's composition
If acellular lung scaffolds are used for recellularization, then native lung architecture is preserved, but effective recellularization requires optimized cell seeding and culture conditions
Solution Approach 1:
The patent applies parameter changes by systematically optimizing culture conditions including oxygen tension (5% O2), media composition (SAGM with supplements), growth factor concentrations (EGF, bFGF, TGF-α), and cell seeding densities. These parameter optimizations enable robust recellularization of acellular scaffolds while preserving lung architecture.
Solution Approach 2:
The patent uses intermediaries by incorporating extracellular matrix proteins (fibronectin, laminin, collagen) and growth factors into the culture system. These intermediaries mediate between the acellular scaffold and stem cells, facilitating cell attachment, proliferation, and differentiation while maintaining the native lung matrix structure.
3Quantity of substance
If stem cell populations are expanded in culture, then sufficient cell numbers are obtained for recellularization, but maintaining stem cell phenotype and proliferation capacity becomes challenging
Solution Approach 1:
The patent applies continuity of useful action by establishing long-term culture protocols that maintain stem cell phenotype throughout expansion. Basal epithelial stem cells are cultured continuously in optimized media containing growth factors (EGF, bFGF, TGF-α) and supplements, allowing expansion to billions of cells while maintaining Krt5+, p63+, and CD44+ markers and proliferation capacity.
Solution Approach 2:
The patent uses self-service by enabling stem cells to self-renew and self-differentiate through autocrine and paracrine signaling. The culture system provides basal media and growth factors that trigger endogenous stem cell pathways, allowing cells to maintain their phenotype and generate sufficient numbers without external intervention beyond initial seeding.
4Manufacturing precision
If Notch pathway inhibition is used to induce distal epithelial phenotype, then surfactant protein expression is increased, but prolonged inhibition may affect overall epithelial development
Solution Approach 1:
The patent applies periodic action by implementing time-controlled Notch pathway inhibition. Gamma-secretase inhibitor (DAPT) is applied during specific culture periods to induce distal epithelial phenotype and surfactant protein expression, then removed or reduced to allow normal epithelial development to proceed, avoiding prolonged inhibition effects.
Solution Approach 2:
The patent uses local quality by applying Notch pathway inhibition specifically to epithelial cells within the recellularized scaffold rather than systemically. This localized treatment induces distal epithelial phenotype in target regions while maintaining overall lung development and avoiding widespread developmental effects.
Data Source
Figure 1A~1B
Figure 1C~1D
Figure 1E
AI summary
Methods of using human airway stem cells in lung epithelial engineering, optionally wherein the cells are contacted with a gamma secretase inhibitor, bioartificial airway organs produced thereby, and the use thereof, e.g., for transplantation. Also methods of treating a bio-artificial matrix with Tenascin-C and/or fibrillin 2.